Effects of the COVID-19 Pandemic on Caregivers of Young Children with Sickle Cell Disease Enrolled in the Engage-HU Trial

• Published in: Blood Vol. 138; no. Supplement 1; p. 1891
• Main Authors: Hood, Anna M, Hildenbrand, Aimee K, Rebitski, Joanna, Stallworth, Jasmine, Johnson, Yolanda, Gomes, Stacey, Whitacre, Catharine, Mara, Constance A, Shook, Lisa M, Quinn, Charles T., Raphael, Jean L., Yates, Amber M, Badawy, Sherif M., Thompson, Alexis A., Smith-Whitley, Kim, Hartung, Helge, King, Allison A., Creary, Susan E, Bhasin, Neha, Reader, Steven K, Meier, Emily R., Tubman, Venee N., Crosby, Lori E.
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 23.11.2021; American Society of Hematology. Published by Elsevier Inc

Background: Hydroxyurea (HU) is the primary medication used to prevent the significant medical and neurologic morbidities of pediatric sickle cell disease (SCD; HbSS or HbSB0 thalassemia). Despite the benefits of HU, it remains under‐utilized likely due to lack of clinician knowledge/training and ne...